Efficacy demonstrated in 2 pivotal Phase 3 trials, PRIME and PRIME21,2
Randomized PRIME (N=151)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=75) Matched placebo for 24 weeks (n=76) PRIME2 (N=160)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=78) Matched placebo for 24 weeks (n=82) |
Study population Patients (>18 years) with:
57% of patients did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy). |
Primary endpoints PRIME (N=151)
Week 24
PRIME2 (N=160)
Week 12
|
Key secondary endpoints
Week 24:
|
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; WI-NRS, Worst Itch numerical rating scale.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the
information you need to get started.